26 results
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
15 Aug 24
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
8:40am
to increases in legal fees, auditing fees, directors & officers liability insurance costs, and employee benefits.
Research and Development Expenses
Research … and administrative
Impairment loss on inventory, property, plant and equipment and other assets
Research and development
Total operating expenses
Loss from
6-K
LSB
LakeShore Biopharma Co., Ltd
10 Jun 24
Report of Foreign Private Issuer
7:01am
for research and development services of RMB198 million and accrued interests, borrowings and other fees of RMB721 million until full payment. The Claimants … allege that Liaoning Yisheng owes them fees for research and development services from as early as 2002, and that the parties had entered into debt
424B3
LSB
LakeShore Biopharma Co., Ltd
8 May 24
Prospectus supplement
8:32am
attributable to increases in provisions for inventory impairment and provisions for trade receivables.
Research and Development Expenses
Research … and administrative
Research and development
Total operating expenses
Loss from operations
Other income (expenses):
Late fees for social security insurance
6-K
EX-99.1
y7w8p8w1 i00d84dy78
19 Apr 24
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
8:03am
POS AM
lr1s2iv
23 Jan 24
Prospectus update (post-effective amendment)
4:18pm
6-K
EX-99.1
bfpe71eqc ihx
22 Jan 24
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
5:10pm
6-K
EX-99.1
rkwkvqrgndwq 8q4na
14 Nov 23
Report of Foreign Private Issuer
12:00am
424B3
tj8h5r7ho2ad1los
25 Sep 23
Prospectus supplement
6:07am
6-K
EX-99.1
j3nao xck13
16 Aug 23
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
8:00am
424B3
bhbhw4dhc4f2giio16
15 Aug 23
Prospectus supplement
8:00am
POS AM
ydo 6gy1ubt6bvjbq2ew
8 Aug 23
Prospectus update (post-effective amendment)
4:06pm
20-F
8gbq 82628
26 Jul 23
Annual report (foreign)
4:02pm
424B3
8n21r
5 Jun 23
Prospectus supplement
4:03pm
F-1/A
vzjki7nz5c txhvff9
12 May 23
Registration statement (foreign) (amended)
4:05pm
F-1
uu98py39oyxfpzf
12 Apr 23
Registration statement (foreign)
8:49am
F-4
ek3ucsjk76v8
28 Dec 22
Registration of securities (foreign)
6:58am
F-4
EX-10.9
t29qsi
28 Dec 22
Registration of securities (foreign)
6:58am
DRS/A
ezm13w31qq73kobz9t
7 Dec 22
Draft registration statement (amended)
12:00am